{"Content: ":"GRAd-COV2 is a COVID-19 vaccine candidate developed by ReiThera Srl and Lazzaro Spallanzani National Institute for Infectious Diseases.[1][2] It is based on a novel replication defective Gorilla Adenovirus and encodes for SARS-COV-2 full length prefusion stabilized Spike protein.[1] More specifically, the vector used is the simian group C adenovirus GRAd32, isolated from a captive gorilla, with a genome deleted of the entire E1 and E3 regions and the native E4 region replaced with the E4 orf6 of human adenovirus 5 (hAd5).[3] This article about vaccines or vaccination is a stub. You can help Wikipedia by expanding it. This article about COVID-19 vaccines is a stub. You can help Wikipedia by expanding it.","Title":"GRAd-COV2 - Wikipedia","KeyID":"11187","URL":"https://en.wikipedia.org/wiki/GRAd-COV2"}